José Baselga, AstraZeneca (ASCO)
April 24, 2020 06:39 AM EDTUpdated 10:23 AM
R&D

Lyn­parza im­proves sur­vival rate in prostate can­cer, giv­ing As­traZeneca and Mer­ck an­oth­er win on PARP front

John Carroll

Editor & Founder

As­traZeneca and its part­ners at Mer­ck can tack on an­oth­er key clin­i­cal win for their block­buster can­cer drug star Lyn­parza. Fol­low­ing up on their suc­cess …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ex­clu­sive: In­sitro makes head­way on the hard­er road, dis­cov­er­ing new ALS drug tar­get

Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force in lat­est job cuts

SiteOne Ther­a­peu­tics, a pain biotech that's part­nered with Ver­tex, nabs $100M

Tessera gets up to $50M from the Gates Foun­da­tion; Tvar­di’s re­verse merg­er

A service from the Financial Times